MaxCyte, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $109.4M
- Price
- $1.06
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.75%
- Volume
- 185.7K
About
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Quick stats
Shares outstanding103.2M
Computed float101.9M
Float / shares98.7%
Cash runway (months)62.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001287098
Websitehttps://www.maxcyte.com
AI Summary
AI-generated1/12
minorneutralexecutive change
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
MaxCyte appointed Sidharth Kapileshwar as Chief Corporate Development Officer, a new addition to the executive team.
Kapileshwar joins from Danaher, where he was VP of Innovation for the Life Sciences Platform, and brings roughly 25 years of corporate development, strategy, and M&A experience across GE Healthcare, Beckman Coulter, and Halma plc.
The hire signals MaxCyte is building out its corporate development capability, which investors may read as preparation for future M&A or partnership activity, though no transaction was announced.